I
Immusoft
Immusoft, a biotechnology company, commercializes technologies that program the human immune system by modifying the DNA in related cells
About Immusoft
Immusoft Corporation, based in Seattle, is a pioneering cell therapy company focused on developing a novel approach to sustained delivery of protein therapeutics using the body's own cells. The company operates in the biotechnology and healthcare market, primarily serving patients with chronic diseases that require long-term treatment solutions. Immusoft's core technology, known as Immune System Programming (ISP), involves collecting a type of immune cell called B cells, programming them to produce specific therapeutic proteins, and then reintroducing these cells into the patient's body. These programmed B cells transform into plasma cells, which act as biofactories to produce and secrete therapeutic proteins continuously over extended periods. This innovative approach aims to provide a more effective and sustained treatment option compared to traditional therapies. Immusoft generates revenue through partnerships, licensing agreements, and potentially future commercialization of its proprietary therapies. The company targets a niche market with high unmet medical needs, positioning itself as a leader in the cell therapy space.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2009
- Headquarters
- Seattle, United States
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 59.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2c
- Investment activity
- 1 company, latest Mar 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Jan 2023 | $8M | — | California Institute for Regenerative Medicine | ↗ |
| GRANTOther financing | Nov 2021 | $4M | — | California Institute for Regenerative Medicine | — |
Growth signals
Latest recorded traffic for Immusoft is 3.1K monthly website visits, up 40.9% over the last three months. Immusoft's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Boston Harbor Angels
The Thiel Foundation
National Institute of General Medical Sciences
National Institutes of Health
California Institute for Regenerative Medicine
Series A10 investors entered at this stage
Founders Fund
Breakout Ventures- TPTechnium Partners
Propel(x)- 6F600 Mile Challenge Fund
Peter Thiel
Tim Draper- RCRBV Capital
DEFTA Partners
Mesa Verde Venture Partners
Series B and later2 investors entered at this stage
Westcott LLC
Ikarian Capital LLC
Other known investors8 additional known investors
Caltech, California Institute of Technology
Bios Partners
Breakout Labs
Global Source Ventures
Invariantes Fund
Julia (Thies) Moore
Small Business Innovation Research
William Hyun
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immusoft on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immusoft’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.